SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Sentinel lymph node biopsy alone is the current surgical axillary treatment for early-stage breast cancer patients with a negative sentinel lymph node (SLN). The possibility to omit axillary dissection also in presence of positive SLNs has been promoted by the American College of Surgeons Oncology Group (ASOCOG) Z0011 randomized trial. Several limitations and evidences of potential selection bias made this trial fairly controversial. Stronger evidence than currently available is needed on the safety of foregoing axillary dissection in well-defined populations of patients with positive SLNs. The Italian multicentre SINODAR ONE randomized trial here presented was designed with this aim.

Original languageEnglish
Pages (from-to)197-200
Number of pages4
JournalBreast
Volume30
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Dissection
Randomized Controlled Trials
Breast Neoplasms
Sentinel Lymph Node Biopsy
Selection Bias
Safety
Population
cyhalothrin
Therapeutics
Sentinel Lymph Node

Keywords

  • Axillary lymph node dissection (ALND)
  • Breast cancer
  • Overall survival (OS)
  • Sentinel lymph node biopsy (SLNB)
  • SINODAR ONE

ASJC Scopus subject areas

  • Surgery

Cite this

@article{535255ced4544e11bb1cdc3f501900f2,
title = "SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes",
abstract = "Sentinel lymph node biopsy alone is the current surgical axillary treatment for early-stage breast cancer patients with a negative sentinel lymph node (SLN). The possibility to omit axillary dissection also in presence of positive SLNs has been promoted by the American College of Surgeons Oncology Group (ASOCOG) Z0011 randomized trial. Several limitations and evidences of potential selection bias made this trial fairly controversial. Stronger evidence than currently available is needed on the safety of foregoing axillary dissection in well-defined populations of patients with positive SLNs. The Italian multicentre SINODAR ONE randomized trial here presented was designed with this aim.",
keywords = "Axillary lymph node dissection (ALND), Breast cancer, Overall survival (OS), Sentinel lymph node biopsy (SLNB), SINODAR ONE",
author = "Corrado Tinterri and G. Canavese and Paolo Bruzzi and Beatrice Dozin",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.breast.2016.06.016",
language = "English",
volume = "30",
pages = "197--200",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes

AU - Tinterri, Corrado

AU - Canavese, G.

AU - Bruzzi, Paolo

AU - Dozin, Beatrice

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Sentinel lymph node biopsy alone is the current surgical axillary treatment for early-stage breast cancer patients with a negative sentinel lymph node (SLN). The possibility to omit axillary dissection also in presence of positive SLNs has been promoted by the American College of Surgeons Oncology Group (ASOCOG) Z0011 randomized trial. Several limitations and evidences of potential selection bias made this trial fairly controversial. Stronger evidence than currently available is needed on the safety of foregoing axillary dissection in well-defined populations of patients with positive SLNs. The Italian multicentre SINODAR ONE randomized trial here presented was designed with this aim.

AB - Sentinel lymph node biopsy alone is the current surgical axillary treatment for early-stage breast cancer patients with a negative sentinel lymph node (SLN). The possibility to omit axillary dissection also in presence of positive SLNs has been promoted by the American College of Surgeons Oncology Group (ASOCOG) Z0011 randomized trial. Several limitations and evidences of potential selection bias made this trial fairly controversial. Stronger evidence than currently available is needed on the safety of foregoing axillary dissection in well-defined populations of patients with positive SLNs. The Italian multicentre SINODAR ONE randomized trial here presented was designed with this aim.

KW - Axillary lymph node dissection (ALND)

KW - Breast cancer

KW - Overall survival (OS)

KW - Sentinel lymph node biopsy (SLNB)

KW - SINODAR ONE

UR - http://www.scopus.com/inward/record.url?scp=84995900161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995900161&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2016.06.016

DO - 10.1016/j.breast.2016.06.016

M3 - Article

AN - SCOPUS:84995900161

VL - 30

SP - 197

EP - 200

JO - Breast

JF - Breast

SN - 0960-9776

ER -